BeyondSpring Inc. Logo

BeyondSpring Inc.

Develops innovative immuno-oncology cancer therapies, including a 'pipeline in a drug' asset.

BYSI | NDAQ

Overview

Corporate Details

ISIN(s):
KYG108301006
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, 7932 FLORHAM PARK
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BeyondSpring Inc. is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies. The company is committed to improving clinical outcomes and raising the standard of care for cancer patients. Its lead asset, Plinabulin, is being developed as a 'pipeline in a drug' for multiple cancer indications. BeyondSpring is also an equity owner of SEED Therapeutics, a company specializing in Targeted Protein Degradation (TPD) technology to discover and develop novel 'molecular glues' for breakthrough therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BeyondSpring Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BeyondSpring Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BeyondSpring Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.
South Korea 187660
HYUNDAI BIOSCIENCE CO., LTD. Logo
Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.
South Korea 048410
iBio, Inc. Logo
AI-powered biotech developing antibody therapeutics for cardiometabolic diseases and obesity.
United States of America IBIO
Ibotta, Inc. Logo
A performance marketing platform offering cash-back rewards to consumers from CPG brands.
United States of America IBTA
ICON PLC Logo
Global CRO providing outsourced development & commercialization for pharma, biotech & device firms.
United States of America ICLR
IDEAYA Biosciences, Inc. Logo
Clinical-stage firm developing precision cancer therapies via synthetic lethality.
United States of America IDYA
IMGT Corporation Limited Logo
Develops a drug delivery platform using ultrasound and nanotech for oncology.
South Korea 456570
IMMERSION CORP Logo
Licenses patented haptic feedback technology for mobile, gaming, and automotive interfaces.
United States of America IMMR
IMMUNIC, INC. Logo
Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.
United States of America IMUX
IMMUTEP Ltd Logo
Developing LAG-3-based immunotherapies for cancer and autoimmune diseases.
United States of America IMMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.